Summary. Previous studies have suggested that nerve regeneration may be defective in patients with diabetic polyneuropathy. Since insulin-like growth factor I (IGF-I) has been shown to stimulate nerve regeneration, and IGF binding protein-1 is acutely regulated by plasma insulin we have investigated the relationships between plasma IGF-I, IGFBP-1, glucose and insulin in Type i (insulin-dependent) diabetic patients with peripheral polyneuropathy. Plasma samples were taken at hourly intervals over an ll-h period (08.00-19.00hours) in order to characterise secretory profiles for 15 Type 1 diabetic patients (eight neuropathic and seven non-neuropathic) and eight non-diabetic control subjects. In the non-diabetic subjects, mean plasma IGF-I levels were stable throughout the 11-h period with a range of 97 gg/l-169 gg/1. In contrast, mean plasma IGFBP-1 levels declined steadily from a high level of 1.99 gg/1 at 08.00 hours to approximately one half (0.86 gg/1) at 15.00 hours. Comparison of areas under the curves revealed significant negative correlations between IGFBP-1 and glucose (-0.88, p =0.01), IGFBP-1 and insulin (.0.75, p =0.016), and IGFBP-1 and IGF-I (.0.68, p = 0.03). A significant positive correlation was found between insulin and IGF-I (+ 0.89, p = 0.001). The diabetic patients had markedly elevated plasma IGFBP-1 levels (area under curve, p = 0.01) and lower plasma IGF-I levels (p = 0.033) even though these patients were hyperinsulinaemic throughout the study period. The neuropathic diabetic patients had grossly elevated IGFBP-1 levels ( ~ = 40 gg/1 at 08.00 hours) which were significantly higher (area under curve, p = 0.05) than in patients without neuropathy ( ~ = 15 gg/1 at 08.00 hours). However, plasma levels of insulin and IGF-I in neuropathic and non-neuropathic subjects were similar, suggesting that the regulation of IGFBP-1 is more resistant to insulin in the neuropathic patients. In contrast to the non-diabetic subjects comparison of area under curve values revealed no positive correlation between insulin and IGF-I or negative correlations between IGF-I and IGFBP-1, and IGFBP-1 and glucose. We conclude that in Type 1 diabetes the relationships between plasma glucose, insulin, IGF-I and IGFBP-1 are clearly abnormal, and these abnormalities are more pronounced in patients with peripheral neuropathy.
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The pathogenesis of diabetic polyneuropathy is still poorly understood, although accumulating evidence suggests that the duration and severity of hyperglycaemia are important [1] . Tissue damage due to hyperglycaemia may be mediated by the consequences of polyol pathway activation and by non-enzymatic glycation [2] . While these may be important factors causing neuronal degeneration, they are probably not sufficient in themselves to explain the diversity of types and severities of clinical neuropathy and neuropathology. We have previously suggested [3] , on the basis of histomorphometric studies of the sural nerve in patients with diabetic polyneuropathy, that regenerative activity is also defective. These observations imply that the effectiveness of nerve fibre regeneration may play a role in determining the outcome of the pathological process in peripheral neuropathy. Because growth factors are important regulators of tissue regeneration, it is conceivable that defective neuronal regeneration in peripheral neuropathy may be due to abnormalities in the activity of neurotrophic growth factors.
A number of studies suggest that insulin-like growth factor I (IGF-I) displays typical characteristics of a neurotrophic paracrine growth factor which is important for nerve regeneration. For example, studies in rats have shown that Schwann cells from peripheral nerves synthesize IGF-I and that the amount of IGF-I increases locally after a crush lesion [4] . Furthermore, in streptozotocin-diabetic rats with impaired nerve regeneration serum IGF-I levels are reduced and locally applied insulin stimulates regeneration in this model and restores serum IGF-I to normal [5] .
IGF-I is influenced by metabofic status since IGF-I activity has been shown to be regulated by insulin and therefore indirectly by glucose [6] . The activity of IGF-I is also [7] . IGFBP-1 has a molecular weight of approximately 25 kDa [8] , is negatively regulated by i~nsulin [9, 10] , and inhibits the activity of IGF-I in vitro [11] . It has been reported to be elevated in the plasma of poorly-controlled diabetic patients [12, 13] , but to date there have been no studies investigating plasma IGFBP-1 in patients with a specific and wellcharacterised long-term complication of diabetes such as peripheral neuropathy. The purpose of the present study was to investigate whether, in patient,s with diabetic neuropathy, there are abnormalities of IGF-I or IGFBP-1 which may contribute to impaired neuronal regeneration. We have examined the relationships between IGF-I, IGFBP-1, glucose and insulin over an ll-h period in the plasma from neuropathic and non-neuropathic Type 1 diabetic patients and non-diabetic subjects.
Subjects and methods
Blood samples were taken via an indwelling catheter at hourly intervals over an ll-h period (08.00-19.00 hours) from 15 patients with Type i diabetes (eight neuropathic and seven non-neuropathic) and eight non-diabetic control subjects. All subjects in the study followed a fixed feeding regimen (i. e. overnight fast and light meals at 07.00, 12.00 and 18.50 hours), and continued with their usual insulin therapy. Neuropathy was characterized as described previously [14] using a standard symptom questionnaire and clinical evaluation of peripheral nerves, quantitative sensory testing of vibration and temperature perception, four cardiovascular autonomic function tests and peripheral nerve electrophysiology of peroneal and sural nerves. Table 1 lists the characteristics of the normal control subjects and diabetic patients sl:udied and some of the neuropathy parameters measured. Blood samples (5 ml) were collected into lithium heparin tubes, centrifuged immediately and the plasma was frozen and stored at -70 ~ prior to assay.
IGF-I radioimmunoassay (RIA)
. Plasma IGF-I was measured by RIA after acid-ethanol extraction according to the method of Daughaday et al. [15] . Ilae antibody used in the assay was a monoclonal antibody (MAb I-5C9) which was generated after immunization of B alb/c mice with recombinant human IGF-I (rhIGF-I) conjugated to human serum c~-globulin (akind gift from Dr. C. A. Morrison, CibaGeigy, Basle, Switzerland). The assay diluent was 0.1 mol/l sodium phosphate buffered saline pH 7.4 containing 0.1% bovine serum albumin (Sigma Chemical Co., Poole, Dorset, UK). Briefly, I25I-labelled rhIGF-I (20,000 cpm/200 gl) was incubated with antMGF-I monoclonal antibody (MAb I-5C9, 200 gl) and 40 gl of extracted sample or standard for 16 h at 4 ~ Separation of bound and free radioligand was with anti-mouse immunoglobulin linked to cellulose (Sac-Cel, Immunodiagnostic systems, Washington, Tyne and Wear, UK) for i h at 37 ~ followed by centrifugation at 600 g for 5 min at 4 ~ rhlGF-I (World Health Organisation) International reference reagent code 87/518 from the National Institute for Biological Standards and Control (London, UK) was used to standardize the assay. The detection limit (defined as a 10 % displacement of the binding at zero dose of IGF-I) was 40 ng/ml. The coefficients of variation (CV) at 88 ng/ml, 250 nNml, and 500 ng/ml, were 25 %, 11%, and 8% respectively. Cross-reactivity with IGF-II and insulin was less than 1% for both peptides and IGF-I levels measured in dilutions of plasma from acromegalic patients gave values which were parallel to the standard curve. In view of the fact that IGF-I levels were to be measured in plasma which may contain high concentrations of IGFBP-1, the potential interference of IGFBP-1 on the IGF-I assay was investigated. IGF-I standards were diluted in human plasma containing 0, 1, 6, 30, and 160 gg/1 of IGFBP-1 and assayed after acidethanol extraction. Standard curves were superimposable (data not shown) showing that at these levels, IGFBP-1 does not interfere with the measurement of IGF-I using this RIA.
IGFBP-1 imrnunoenzyrnetric assay. Plasma IGFBP-I was measured with a two-site immunoenzymetric assay (IEMA; Medix Biochemica, Kaunianen, Finland). The assay used two MAbs, which recognize distinct epitopes on the IGFBP-1 molecule. One of the antibodies was immobilized on a microtitre plate and the other MAb was conjugated to horseradish peroxidase (HRP). Standardization of the assay was with human IGFBP-1 purified from amniotic fluid (lot 307/3235; Behring Institute, Marburg, FRG). The assay protocol involved incubating 20 gl of standards, controls, and plasma samples with 80 gl of assay diluent in the MAb-coated microtitre wells. After 30 min at room temperature, the wells were aspirated and washed three times with assay diluent (300 gl). MAb-enzyme conjugate (100 gl) was then added to each well and incubated for 30 min at room temperature. The plates were thoroughly washed as above and 100 gl of the HRP-substrate solution was added. After 10 min the absorbance at 414 nm was measured. The minimum detection limit of the assay was 0.4 gg/1 (2 SD from the zero standard) and the working range was 0.4.160 Bg/1 (CV < 5 % ).
Glucose measurement. Plasma glucose was measured using a standard automated glucose oxidase technique.
Insulin RIA. Plasma insulin was measured by RIA as described previously [16] . Briefly, the assay employed a guinea-pig antiserum to human insulin (ICN/Flow Laboratories, Rickmansworth, Herts, UK), ~Z%labelled insulin (Medgenix, High Wycombe, Bucks, UK) ( 9 ) and non-neuropathic ( 9 ) Type 1 diabetic patients. All subjects followed a fixed eating pattern which included an overnight fast and light meals at 07.00,12.00 (L) and 17.45 hours (D Fig.2 . Plasma insulin-like growth factor I (IGF-I) concentrations measured in normal subjects ( 9 and Type i diabetic patients with peripheral neuropathy ( 9 ), and without neuropathy ( 9 ) . All subjects followed a fixed eating pattern which included an overnight fast and light meals at 07.00, 12.00 (L) and 17,45 hours (D). Insulin was administered to diabetic patients at 07.00 and 18.00 hours. Values are expressed as mean + SEM as tracer and human insulin (WHO 1st International reference preparation) as standard. Separation of bound and free radioligand was by charcoal separation. The assay had a detection limit of 1.0 mIU/l, an inter-assay CV of less than 5 % between 1-250 mIU/1, and an intra-assay CV of less than 10 % between 2-110 mIU/1.
C-peptide measurement. Postprandial (13.00 hours) plasma C-peptide concentrations were measured by RIA (Serono Diagnostics, Woking, Surrey, UK).
Statistical anaIys&
Curves were plotted of IGF-I, IGFBP-1, glucose and insulin concentration against time and the area under each curve (AUC) was calculated as a summary statistic for each ii-h profile. The Mann-Whit-S. R. Crosby et al.: Elevated IGFBP-1 and diabetic neuropathy uey test for non-parametric data was used to compare AUC values between groups and the relationships between each factor were examined using Pearson correlation coefficients.
Results
The clinical details of the subjects included in this study are summarised in Table 1 which shows that there were no significant differences in the age range, or body mass index between any of the three subject groups. The duration of diabetes was similar between neuropathic and nonneuropathic patients. There were marked differences between the groups in the ll-h plasma profiles of IGFBP-1 (Fig. 1) . In nondiabetic subjects the mean IGFBP-1 levels ranged from 0.86 gg/1 to 1.99 gg/t, and a rapid fall in plasma IGFBP-1 occurred after 13.00hours to the lowest level at 15.00 hours (a decrease of 48 %) reflecting acute negative regulation of IGFBP-1 by insulin (which peaked at 13.00 hours following the midday meal). IGFBP-1 was much higher in the plasma of all of the diabetic patients (range, 11-40 ~tg/1 for the neuropathic group, 2.3-15 gg/1 for the non-neuropathic group), and there was a clear diurnal variation, with the highest levels at 08.00 hours followed by a rapid fall during the morning. Comparison of the individual AUC values revealed that IGFBP-1 levels were significantly higher (p --0.05) in the neuropathic group than in the non-neuropathic group.
Such differences were not reflected in plasma IGF-I levels (Fig. 2) . In non-diabetic subjects IGF-I levels varied from 97 gg/1 to 169 gg/1 and there was no significant diurnal variation. Mean IGF-I levels in diabetic plasma were lower in both neuropathic (range, 44-104 gg/1) and nonneuropathic (range, 50-109 gg/1) patients, but no significant difference was found between these two groups.
As expected, glucose was elevated in plasma from diabetic patients over the 11-h study period (Fig. 3) and comparison of 11-h AUC values (08.00-19.00 hours) revealed no significant difference between neuropathic and non-neuropathic diabetic patients. However, plasma glucose levels were clearly lower during the morning in the non-neuropathic group than the neuropathic group and comparison of AUC values between 08.00 and 13.00 hours revealed a highly significant difference between these groups (p = 0.0006).
Insulin levels in non-diabetic subjects (Fig.4 ) ranged between 6.2 and 26.4mIU/1, with a clear peak at 13.00 hours following the midday meal. In the Type 1 diabetic patients the mean plasma insulin levels (following injection at 07.00 hours) peaked at 09.00 hours (nonneuropathic) and 10.00 hours (neuropathic) after which there was a steady decline. Levels in both groups remained higher than those of non-diabetic subjects (p =0.033) throughout the 11-h period (range, 12.8-24.4 mIU/1 for neuropathic patients and 14.7-31 mIU/l in non-neuropathic patients) except at 13.00 hours. There was no difference in the insulin levels (AUC) between neuropathic and non-neuropathic patients. C-peptide was undetectable in plasma from all of the diabetic patients at 13.00 hours, indicating the absence of endogenous insulin.
In the 11-h profiles there were significant inverse correlations (AUC values) between IGFBP-1 and glucose Time (h) l~ig.3. Plasma glucose concentrations measured hourly for 11 h in eight non-diabetic subjects ( 9 eight neuropathic Type 1 diabetic patients ( 9 and seven non-neuropathic diabetic patients ( 9 ). All subjects followed a fixed eating pattern which included an overnight fast and light meals at 07.00, 12.00 (L) and 17.45 hours (D). Insulin was administered to diabetic patients at 07.00 and 18. and insulin (-0.66, p = 0.026) was retained in the neuropathic group but not in the non-neuropathic group.
Discussion
Our results show that there are clear abnormalities in the regulation and circulating levels of IGF-I and IGFBP-1 in Type 1 diabetes, and that there are changes, particularly in IGFBP-1 which are more pronounced in neuropathic as compared to nomneuropathic patients. In non-diabetic subjects insulin is negatively correlated with IGFBP-1 and positively correlated with IGF-I and our results are in agreement with those of other workers [17] who have investigated the relationship between insulin, IGF-I and IGFBP-1 in plasma. This is consistent with the concept that insulin is a major regulator of IGF-I and IGFBP-1 in plasma and that the anabolic effects of insulin are mediated through changes in IGF-I activity. The rapidity with which insulin regulates IGFBP-1 secretion has been demonstrated previously [9] and is reflected in the present study by the rapid fall in plasma IGFBP-1 within 3 h of a midday meal. These fluctuations appear to be superimposed on the diurnal variation of plasma IGFBP-1 (i. e. levels are higher early in the morning and fall progressively throughout the day) suggesting that factors other than insulin may also have a role in regulating IGFBP-1. Fluctuations of plasma cortisol for example are similar to those of IGFBP-1 and in view of the recent reports on glucocorticold-stimulated IGFBP-1 secretion [18] , it is possible that these diurnal rhythms are related. In contrast to IGFBP-1, we did not find that plasma IGF-I levels responded rapidly to changes in plasma insulin. The positive correlation (AUC values) between these two peptides may therefore be due to an effect of insulin level and activity on IGF-I secretion over prolonged periods of time.
In the non-neuropathic diabetic patients there was a gross elevation of plasma IGFBP-1 and a much more pronounced diurnal variation. A similar pattern has been reported by others [19] , however, our study shows that this elevation of IGFBP-1 in diabeticpatients occurred despite persistent hyperinsulinaemia. Plasma IGFBP-1 levels were therefore inappropriately high for the circulating insulin levels in comparison with non-diabetic control subjects. Plasma IGF-I levels were also reduced in non-neuropathic diabetic patients relative to non-diabetic control subjects, as were plasma IGF-II levels (data not shown). Taken together, these results suggest a lack of effect of insulin on hepatocytes (the major source of circulating IGF-I and IGFBP-1). This may simply reflect non-physiological insulin administration (i. e. the physiological regulation ofIGFBP-1 and IGF-I is by pulses of pancreatic insulin delivered through the hepatic portal vein) or may suggest a degree of resistance to insulin regulation, particularly the inhibitory effects of insulin on IGFBP-1 secretion. Irrespective of the mechanism, these abnormalities are sufficient to disrupt the normal relationships which exist between insulin, IGF-I, and IGFBP-1 in plasma.
In neuropathic diabetic patients, these abnormalities were even more pronounced and we found that the mean plasma IGFBP-1 levels at 08.00 hours were 2.7 times higher than in non-neuropathic patients. Given that these differences were not due to differences in insulin levels, the presence of anti-insulin antibodies (which were more prevalent in the non-neuropathic group, data not shown) or to residual endogenous insulin in the non-neuropathic group (i. e. postprandial C-peptide was undetectable in both groups), it seems likely that the neuropathic patients in our study were more resistant to the hepatic effects of insulin on IGFBP-1 secretion than non-neuropathic patients. The significantly higher morning glucose levels in these patients may mean that this is part of a more generalized resistance to the actions of insulin.
The consequences of elevated circulating IGFBP-1 levels are unknown, but one can speculate that they may be relevent to a number of diabetic complications involving abnormalities in cellular growth or regeneration. Several in vitro studies have shown that IGFBP-1 can inhibit the binding of IGF-I to its cell surface receptors and thereby inhibit IGF-I action [11] . Furthermore, IGFBP-1 levels in plasma from diabeticpatients are also associated with IGF-I inhibitory activity on cartilage sulphation [20] . Thus, current opinion favours an inhibitory role of IGFBP-1 on the action of IGF-I, although there have been reports that IGFBP-1 can enhance the mitogenic response of some cell types to IGF-I under certain conditions [21] . The relationship between circulating IGFBP-1 and local 1GFBP-1 concentrations in neuronal tissue is unknown at present. In view of a recent report [22] that capillaries are permeable to IGFBP-1 and that insulin increases transcapillary permeability, it seems likely that tissue levels of IGFBP-1 will also be elevated in poorly-controlled diabetic patients, particularly those with hyperinsulinaemia.
